UroGen Pharma Ltd.
URGNHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeUroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. At a $1.96B market cap, UroGen Pharma Ltd. ranks as a small-cap company within healthcare. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Market Cap
$1.96B
Beta
1.57
P/E (TTM)
—
P/E (Fwd)
29.18
EPS (TTM)
$-2.75
EPS (Fwd)
$1.38
ROE
—
ROA
-27.0%
Cash
$140.3M
Total Debt
$197.1M
Free CF
-$109.3M
52W Change
163.5%
Annual Financials
Cash vs Debt
UroGen Pharma Ltd. carries $197.1M in total debt against $140.3M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$109.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has grown from $64.4M (2022) to $109.8M (2025), reflecting a 71% increase over the period.
UroGen Pharma Ltd.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing URGN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.